New hope for advanced cancer? experimental drug MHB046C enters human trials

NCT ID NCT06985355

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MHB046C

What this could lead to

If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.

What could go wrong

This is a very early, first-in-human trial, so the drug may not work or could cause unexpected side effects. Success in early phases does not guarantee later approval.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••